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Positive In Vivo Selection of the HIV-1 Envelope Protein gp120
Occurs at Surface-Exposed Regions
Abstract
The rapid evolution of human immunodeficiency virus (HIV) envelope represents a major challenge to
vaccine and drug development, particularly because the underlying mechanisms are not completely
understood. To explore whether distinct patterns of positive selection within the envelope glycoprotein
(gp) 120 exist and are associated with functionally relevant domains, we conducted a long-term survey
of sequence evolution in 20 HIV-1-infected persons who interrupted antiretroviral therapy. In total,
1753 clonal sequences encompassing the C2-V3-C3 region of gp120 were derived. Strikingly, positively
selected amino acids mapped almost exclusively (P=.0003) to externally accessible residues on the
gp120 crystal structure. The current understanding of envelope structure and function associates the
main determinants of viral entry and the targets for neutralizing antibodies with these exterior regions of
gp120, strongly suggesting that the observed adaptive evolution of these sites occurs in response to
respective selective forces.
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Positive In Vivo Selection of the HIV-1 Envelope
Protein gp120 Occurs at Surface-Exposed Regions
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The rapid evolution of human immunodeficiency virus (HIV) envelope represents a major challenge to vaccine
and drug development, particularly because the underlying mechanisms are not completely understood. To
explore whether distinct patterns of positive selection within the envelope glycoprotein (gp) 120 exist and are
associated with functionally relevant domains, we conducted a long-term survey of sequence evolution in 20
HIV-1–infected persons who interrupted antiretroviral therapy. In total, 1753 clonal sequences encompassing
the C2-V3-C3 region of gp120 were derived. Strikingly, positively selected amino acids mapped almost exclu-
sively ( ) to externally accessible residues on the gp120 crystal structure. The current understandingPp .0003
of envelope structure and function associates the main determinants of viral entry and the targets for neu-
tralizing antibodies with these exterior regions of gp120, strongly suggesting that the observed adaptive
evolution of these sites occurs in response to respective selective forces.
HIV evolves rapidly in vivo because of its high repli-
cation rate of – per day [1] and because8 101 10 1 10
of the relatively poor fidelity of the reverse transcription
(RT) process. Compelling evidence exists indicating
that intrahost evolution is not random but is driven by
continuous selection pressure from immune responses
[2]. However, the relative contributions of neutralizing
antibodies, helper T cells, and cytotoxic T lymphocytes
(CTLs) in controlling viral replication in vivo and in-
ducing selection pressure are incompletely understood.
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Among the different HIV genes, env, which encodes the
viral envelope proteins gp120 and gp41, exhibits the
highest evolutionary rate, with increases of ∼1% per
year in divergence and diversity in the C2-V5 region
of gp120 [3]. Positively selected sites were frequently
found within C2-V3-C3 in earlier cross-sectional stud-
ies [4–6]. The third variable loop (V3) of the HIV-1
envelope protein gp120 contains features essential for
HIV binding to its receptors and is a determinant of
viral tropism and coreceptor usage (CXCR4 or CCR5)
[7, 8]. Type-specific neutralizing responses directed
against the V3 loop are commonly found in infected
individuals [9, 10] and have been suggested to drive
the high evolutionary rate of this variable region [3].
We previously studied viral diversity [11] in patients
with chronic HIV-1 infection who underwent con-
trolled treatment interruption after receiving antiret-
roviral treatment for 16–40 months [12–16]. In this
cohort, lower pretreatment diversity was associated
with spontaneous control of viremia, reduced viral rep-
lication capacity, and higher neutralizing antibody ac-
tivity against autologous virus but not with the breadth
or magnitude of the CTL response [11]. Longitudi-
nal evolutionary analysis suggested that stronger au-
tologous neutralizing antibody responses contributed
314 • JID 2007:196 (15 July) • Joos et al.
Table 1. Patient characteristics.
Patienta
Observation
period, years
Time without
ART, years
Pretreatment
diversityb
Divergence
over timeb
Adaptation
ratec
105 7.6 4.2 0.68 1.44 0.100
106 7.8 4.1 0.71 1.42 0.117
107 6.5 3.3 2.12 1.67 0.066
109 3.8 0.3 4.02 2.05 0.000
111 3.2 1.1 4.66 1.29 0.240
112 4.1 0.8 1.61 0.13 0.000
113 7.5 3.9 2.27 1.66 0.201
114 6.7 3.2 2.74 2.09 0.246
115 6.0 3.2 1.60 0.97 0.134
117 7.1 3.2 0.88 0.33 0.050
118 7.1 3.6 0.94 1.97 0.163
119 3.3 1.2 1.60 0.81 0.161
120 6.2 3.1 2.97 1.02 0.110
121 3.8 1.4 1.23 0.97 0.233
122 7.4 4.0 3.34 1.58 0.136
123 6.9 3.2 2.87 4.46 0.177
124 4.2 1.9 2.93 2.51 0.188
126 6.9 3.0 3.87 1.80 0.186
127 3.9 1.1 2.95 0.13 0.081
128 6.6 3.5 4.90 2.35 0.096
Median 6.6 3.2 2.51 1.51 0.135
a Other characteristics, such as viral load, CD4 cell count, coreceptor usage, and virus subtype,
have been reported elsewhere [11, 15]. Identification codes correspond to those given previously.
b Genetic distance estimates were obtained by use of the Tamura-Nei 6-parameter model, and
analyses were conducted by use of MEGA software (version 3.1) [18].
c Total no. of adaptive events per month, as determined by the method of Williamson [19].
to virus control in a subset of these chronically infected pa-
tients [17].
Because our previous observations suggested a potential role
of the neutralizing antibody response in restricting viremia in
vivo and, hence, driving HIV envelope evolution, we conducted
in the present study a long-term survey of the sequence evo-
lution of the envelope region (spanning the V3 loop and its
flanking domains) in a cohort of 20 patients. We thereby aimed
to formally determine whether positive selection occurs, wheth-
er hotspots for positive selection can be located, and whether
these mutated codon sites fall within structurally relevant do-
mains. We found that positively selected amino acid changes
occurred predominantly at exposed locations on the virion sur-
face, conferring high external accessibility. This suggests that
these sites evolved in response to selective pressure induced by
neutralizing antibodies. The structural model of gp120 con-
verged remarkably well with our evolutionary analysis in HIV-
1–infected patients. Moreover, the results confirm the utility of
maximum likelihood–based genetic algorithms in accurately
detecting and monitoring selection pressure.
PATIENTS, MATERIALS, AND METHODS
Nomenclature of HIV envelope substructures. The HIV-1 en-
velope glycoprotein consists of the surface moiety gp120, which
is bound to the transmembrane protein gp41. The primary
structure of gp120 can be subdivided into 5 relatively conserved
regions and 5 variable loops (C1-V1-V2-C2-V3-C3-V4-C4-V5-
C5, from amino to carboxy terminus).
Subject selection and study design. In total, 29 patients
were enrolled at the University Hospital Zu¨rich into the Swiss-
Spanish Intermittent Treatment Trial [12–14]. In the present
analysis, we included those who remained without antiretroviral
therapy after completion of the trial provided that polymerase
chain reaction (PCR) amplification was successful. Detailed pa-
tient characteristics [11, 15] (see also table 1) and results of
the clinical trial [12] have been reported elsewhere. Written
informed consent was obtained from all patients, in accordance
with the guidelines of the Ethics Committee of the University
Hospital Zu¨rich.
RNA extraction, RT-PCR, cloning, and sequencing. RNA
was extracted from 0.8–0.9 mL of plasma; subsequently, for
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each time point, 16 representative clonal sequences spanning
the C2-V3-C3 region of HIV-1 env were derived as described
elsewhere [11]. Overall, 109 longitudinal samples from 20 pa-
tients were analyzed, resulting in a total of 1753 clonal se-
quences (31–190/patient) obtained from before antiretroviral
therapy as well as during and after treatment interruptions. The
average misincorporation rate was 0.18%, as tested by ampli-
fication of HIV-1 strain YU2 (GenBank accession number
M93258) [11]. The reproducibility of sequencing was shown
by duplicate analysis of 32 clones (error rate, 0/26,000 bp). The
accuracy of the method was tested by analyzing 2 patient sam-
ples (1 of high diversity and 1 of low diversity) in parallel by
limiting-dilution cloning, resulting in almost identical quasi-
species composition.
Phylogenetic analyses. Sequences were edited and aligned
by use of Lasergene software (version 5.08; DNASTAR). Align-
ments were manually corrected to adjust sequence gaps with
the reading frame. Phylogenetic analyses were conducted by
use of MEGA software (version 3.1) [18]. Genetic distances
were estimated by use of the Tamura-Nei 6-parameter model.
A neighbor-joining phylogenetic tree was constructed by use
of MEGA using the sequences of HIV strains HXB2 (GenBank
accession number K03455) and JR-FL (GenBank accession
number U63632) as references and by bootstrapping (500 rep-
lications). Screening for recombination was performed on the
data from each patient individually by use of single-breakpoint
analysis and the Bayesian information criterion of Schwarz
(HyPhy software package; version 0.99 [20]). No evidence of
recombination was found in any of the data sets.
Positive selection detection. Average numbers of adaptive
changes over the entire gene fragment were determined ac-
cording to the method of Williamson [19]. Site-by-site iden-
tification of positively selected positions was assessed by use of
single-likelihood ancestor counting, fixed-effects likelihood,
and random-effects likelihood methods, executed in the HyPhy
software package by use of the algorithms proposed by Kosa-
kovsky Pond and Frost [21, 22]. Briefly, the optimal time-
reversible substitution model was determined for each patient
after removal of duplicate sequences; then, depending on the
size of the data set, each or a subset of the maximum likelihood–
based analyses were performed on the datamonkey platform.
Surface accessibility. Solvent-accessible surface area was
quantified by use of the AREAIMOL program (CCP4i, version
5) [23, 24], employing a solvent-sphere radius of 1.4 A˚. Relative
solvent accessibility was calculated as the accessible area divided
by the maximum accessible area of the amino acid in an ex-
tended tripeptide conformation (Ala-X-Ala) [25]. Residues
with solvent accessibility of 15% or more were considered to
be surface exposed.
Glycosylation sites. Potential N-linked glycosylation sites
were determined by use of the N-glycosite tool from the Los
Alamos HIV sequence database (available at: http://www.hiv
.lanl.gov/content/hiv-db/GLYCOSITE/glycosite.html).
Statistical analyses. The number of sequences per patient
was variable. Determination of the substitution model, screen-
ing for recombination, and detection of positive selection was
performed individually for each patient. Spearman’s correlation
with the Bonferroni adjustment for multiple comparisons was
used to test the association between the number of positively
selected sites and various patient-specific parameters. Finally,
all positively selected sites were pooled for mapping to struc-
tural data and solvent-accessible areas. Comparison of the pres-
ence or absence of positive selection for both buried ( )np 46
and surface-exposed ( ) residues was made by 2-tailednp 69
Fisher’s exact test. Three positions were excluded (310, 311,
and 356), because no surface-accessibility data were available
from the respective gp120 structure of JR-FL (Protein Data
Bank accession code 2B4C) [26]. The average difference be-
tween the nonsynonymous substitution rate and the synony-
mous substitution rate ( ) for buried and exposed res-d  dN S
idues were compared by use of the 2-sided Mann-Whitney U
test. The x2 test and the parametric unpaired t test gave com-
parable results; however, we did not test for normality of dis-
tribution. GraphPad Prism (version 4; GraphPad Software) was
used for statistical analyses.
Nucleotide sequence accession codes. All reported se-
quences have been deposited in GenBank and were assigned ac-
cession numbers EF424791–EF426096, DQ002058–DQ002345,
AY656534–AY656549, AY656440–AY656471, AY656249–
AY656312, AY375663–AY375678, AY375616–AY375630, and
AY375568–AY375583.
RESULTS
Long-term evolution of HIV envelope C2-V3-C3 in vivo. To
study envelope evolution, a total of 1753 clonal sequences of
the gp120 C2-V3-C3 region were obtained from the plasma of
20 HIV-1–infected patients over a median of 6.6 (range, 3.2–
7.8) years by use of an established RT-PCR and cloning strategy
[11]. During the observation period, the patients were enrolled
in a clinical trial of treatment interruption after receiving an-
tiretroviral treatment for a median of 2.7 (range, 1.4–3.3) years.
The median antiretroviral drug–free interval of the cohort was
3.2 (range, 0.3–4.2) years (table 1). Phylogenetic reconstruction
revealed highly specific clustering of individual patient se-
quences, excluding cross-contamination between subjects and
contamination with laboratory strains (figure 1). The inferred
net divergence of intraindividual sequences from the first (pre-
treatment) and last time points sampled averaged 1.5% (range,
0.1%–4.5%). This corresponds to an average increase in viral
population divergence of 0.8% per year during the period with-
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Figure 1. Phylogenetic tree. Shown is an inferred neighbor-joining phy-
logenetic tree of clonal HIV-1 env C2-V3-C3 sequences derived from 20
patients. Elongated triangles represent the compressed subtrees con-
taining 31–190 clones isolated from the plasma of each patient before
antiretroviral therapy and after treatment interruption. The length of the
triangle corresponds to the respective intrapatient diversity; its thickness
is proportional to the no. of taxa. HXB2 and JR-FL were included as
external reference strains. The bar denotes 2% nucleotide divergence
and diversity (determined by use of MEGA software); bootstrap values
are indicated below the branches and correspond to 500 replications.
out antiretroviral therapy and is in agreement with previously
reported divergence rates of 1% per year [3].
Detection of positive selection. To quantify the positive se-
lective pressure on the envelope C2-V3-C3 region, we defined
patient-specific adaptation rates as the number of adaptive
changes introduced per time interval compared with the pre-
treatment consensus sequence, according to the method of Wil-
liamson [19]. This conservative approach is based on counting
the total number of nonsynonymous substitutions and adaptive
mutations that have reached a high frequency (150%) and
corrects for selectively neutral changes. We found an average
of 4.6 (range, 0–10) adaptive events evolving between the first
and last time point analyzed. The corresponding rate of 0.135
(range, 0–0.25) adaptive changes per month of untreated in-
fection closely reflects the rate of 0.106 changes per month
determined in HIV env C2-V3 sequences in adult chronic in-
fection [19]. To identify positions where positive selection had
occurred, we next evaluated the in vivo amino acid changes in
the C2-V3-C3 region on a site-by-site basis by use of single-
likelihood ancestor counting, fixed-effects likelihood, and/or
random-effects likelihood methods, executed in the HyPhy
software package [21]. On the basis of the algorithms proposed
by Kosakovsky Pond and Frost [21, 22], 3 (range, 0–10) amino
acid sites per patient were subject to positive selection on av-
erage. Across all 20 patients, 35 positively selected positions
were detected (figure 2).
In some patients, only the result of the most conservative
single-likelihood ancestor counting method could be obtained,
because the data set was too large to run the computationally
more complex methods. In contrast, for data sets of small or
moderate size, the fixed-effects and random-effects likelihood
methods appeared to yield more power. However, when only
amino acids identified as positively selected by single-likelihood
ancestor counting were examined, the conclusions of the sta-
tistical analyses remained unchanged (i.e., P values remained
!.05). This confirms the finding of Kosakovsky Pond and Frost
[21], who analyzed simulated data as well as HIV-1 env and
pol sequences and found that the 3 methods arrived at similar
conclusions.
No correlation was found between the number of positively
selected amino acid sites and plasma viral load observed over
time in these 20 patients (pretreatment, rebounds during treat-
ment interruption, postinterruption plateau, and area under
the curve). We also evaluated neutralizing antibody titers, CTL
response, helper T cell response, gp120 titers, HIV DNA levels
in peripheral blood mononuclear cells, and duration of HIV
infection; a variety of genetic host polymorphisms in the genes
for CCR2, CCR5, CX3CR1, RANTES, macrophage inflam-
matory protein–1a, stromal-derived factor–1, and interleukin-
10; and HLA types obtained in our previous study [11], but
none of these parameters was found to be associated with the
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Figure 2. Positive selection. Shown are positively selected sites (gray) in the gp120 C2-V3-C3 region, as determined by HyPhy software [20, 21].
The analysis included 1753 clonal sequences obtained from the plasma of 20 HIV-1–infected patients. Position nos. and amino acid residues relative
to HXB2 gp120 are given for reference.
degree of positive selection. However, this analysis was based
on data limited to a relatively short period of time. Larger lon-
gitudinal studies would be required to define such correlations.
Mapping to gp120 structure. Although structural infor-
mation on gp120 has been limited, the crystal structure of the
V3-containing envelope glycoprotein core was recently resolved
[26]. Truncated gp120 of the R5-tropic strain JR-FL was crys-
tallized in complex with 2 domains of the CD4 receptor and
the Fab fragment of an antibody (X5) to the coreceptor binding
site. The resulting structural data allowed us to analyze amino
acid residues that had evolved under positive selection in vivo
in terms of their spatial orientation. Strikingly, most residues
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Figure 3. Structure of the HIV envelope protein gp120. Most positively selected amino acids are found at solvent-exposed positions. A, Ribbon
representation of gp120 JR-FL (Protein Data Bank accession code 2B4C) [26]. Side chains of positively selected amino acids are colored red and are
shown as stick models. The stretch of amino acids analyzed in the present study is subdivided into 4 regions, as follows: residues 248–267 (magenta),
a region that is mostly buried within the glycoprotein; residues 268–296 (blue), the N-terminal flank of the V3 loop; residues 297–330 (green), the
V3 loop; and residues 331–363 (yellow), the C-terminal flank adjacent to the V3 loop. B, a-Helix, comprising residues 335–355 and viewed along the
helical axis. Side chains of amino acids belonging to the helix are shown as stick models, with positively selected residues highlighted in red. C, b-
Strand, comprising residues 290–297. For clarity, residues 325–347 were removed in this representation. The figure was generated by use of the
program PyMOL (available at: http://www.pymol.org/).
at the positively selected sites mapped to solvent-exposed sur-
faces of the gp120 core (figure 3). Detailed analysis of the spatial
positioning of the positively selected amino acids showed that
the majority of the changed residues extended into the sur-
rounding space, rendering them available for interactions with
the viral receptors or neutralizing antibodies.
To further visualize and quantify the surface accessibility
within the C2-V3-C3 of the gp120 core structure model, we
assessed the solvent-accessible surface area by use of the method
of Lee et al. (AREAIMOL; CCP4i version 5), employing a sol-
vent-sphere radius of 1.4 A˚ [23, 24]. The accessible area of a
given amino acid residue is thereby calculated by a “rolling
ball” algorithm, which performs a virtual screen of the 3-di-
mensional protein structure by use of a probe sphere with the
approximate diameter of a water molecule. A residue was con-
sidered to be exposed if its relative solvent accessibility (defined
as the ratio of the accessible area within the 3-dimensional
structure to that in an extended tripeptide conformation [Ala-
X-Ala] [25]) was 15% or more. Overall, in our cohort higher
rates of nonsynonymous than synonymous substitutions were
found to occur at positions coding for the surface-exposed
amino acids of the JR-FL gp120 crystal structure model (average
of normalized by single-likelihood ancestor counting;d  dN S
Mann-Whitney ). Positively selected changes identi-Pp .002
fied by at least 1 of the 3 likelihood methods were associated
almost exclusively (29/34 evaluable sites; Fisher’s exact Pp
) with amino acid positions that had high external ac-.0003
cessibility (figure 4). Of note, the frequency of positive selection
was highest at the locations flanking both ends of the V3 loop
(26/62 positions, compared with 9/32 in the V3 loop). The
almost exclusive colocalization, as determined by maximum-
likelihood algorithms, of positively selected amino acid residues
with positions of high surface accessibility in the 3-dimensional
structure further validates the use of bioinformatics in sequence
analysis and underscores the potential of these methods in de-
tecting biological relevant changes.
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Figure 4. Surface accessibility. Shown is an overlay of relative solvent
accessibility calculated for each amino acid of the 3-dimensional JR-FL
envelope structure (black) and specific homologous sites within the C2-
V3-C3 region, in which significant positive selection has been detected
in at least 1 patient by codon-based likelihood models (red dots). Amino
acid numbering corresponds to gp160 of the reference strain HXB2
(GenBank accession no. K03455). Shaded areas represent the position of
the buried region (magenta; residues 248–267) and the V3 loop (green;
297–330) as well as its N-terminal (blue; 268–296) and C-terminal (yellow;
331–363) flanking regions. Green arrows indicate potential N-linked gly-
cosylation sites. Three residues missing in the JR-FL structure (brown)
were excluded from all analyses.
Given that the extent of glycosylation in gp120 is highly
variable and that both increases and decreases in glycosylation
have been suggested to confer resistance to neutralization [10,
27], we specifically tracked changes in potential N-linked gly-
cosylation sites (figure 4). Although longitudinal variations in
multiple glycosylation sites within the C2-V3-C3 region were
frequently observed (4 sites per patient affected over time;
range, 1–8 sites), positive selection at potential glycosylation
sites was found in only half of the patients (total of 13 sites in
10 patients).
DISCUSSION
Our analysis of molecular evolution within the region encom-
passing the envelope C2-V3-C3 domain has revealed that
amino acids at exposed locations on the virion surface with
high external accessibility are predominantly positively selected.
The present data support the concept that evolution of these
sites occurs in response to selective pressure, which can be
envisioned to be induced by neutralizing antibodies or adap-
tations in the receptor interaction necessitated by the expansion
of cellular tropism (see Pantophlet and Burton [28] for a com-
prehensive review of the biological aspects and structural
features of the HIV envelope protein gp120). Notably, the
structure of gp120 described by Huang et al. [26] and our
evolutionary analysis of in vivo–derived sequences converge
remarkably well. This underscores that, even though this crystal
structure is based on a partially truncated and monomeric form
of gp120, it appears to closely represent the structure of the
biological relevant oligomeric gp120 on the virus. This is best
exemplified by the consistency with which residues that are
positively selected in vivo correspond to externally accessible
amino acids in the model and highlights the potential these
structural models have. Furthermore, the similar mutation pat-
terns observed among widely divergent virus strains (JR-FL and
patient specimens) also suggest that the 3-dimensional structure
of gp120 is quite conserved. Looking at the different regions
of gp120 instead of individual residues, it is not unexpected
that the domains flanking the V3 loop undergo a high level of
selective pressure, relative to the portions that are buried within
the glycoprotein. However, analysis of a larger segment of gp120
would be required for a balanced overview. It is also important
to note that the structure was derived from gp120 crystallized
in the CD4-bound conformation. Because different residues
are exposed in the unbound state or on functional envelope
protein oligomers, the observed mutations in the V3 loop re-
gion over time must not necessarily imply escape from V3 loop–
specific binding antibodies. Additionally, the occurrence of
compensatory mutations due to changes elsewhere in the en-
velope cannot be excluded, and it is also not clear whether the
preferential mutability of surface residues is related to a high
autologous response in the selected cohort of patients under-
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going treatment interruption. Furthermore, host immune-se-
lection pressure could also be exerted by envelope-specific T
cell responses, although, on the basis of our data, we could not
find a correlation. CTLs have been shown to effectively atten-
uate viral replication [29]. Consequently, CTL escape mutants
may arise early during HIV-1 infection. In a longitudinal study
of HIV env evolution by Ross and Rodrigo [30], the sites under
positive selection appeared to be associated with helper T cell
epitopes in some patients.
In summary, our analysis of adaptive amino acid changes in
the region of gp120 encompassing the V3 loop has brought to
light substantial evidence that viral evolution in this domain is
shaped by an ongoing competition between host and pathogen.
Studies based on even larger longitudinal sequence data sets
should be considered to define whether inter- or intrasubtype
relevant hotspots of adaptive mutation exists, because these
could be substantially important components of future vaccine
and drug design.
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